Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Abeona Therapeutics Inc.NASDAQ: ABEO
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 investing cash flow of $4.96M rose 17.8% year over year, behind the +488.7% change in trailing-twelve-month investing cash flow. Sequentially, it fell 48.1% from the prior quarter.
Context
- Investing cash flow amounted to 1804.6% of revenue in FY2025.
- Investing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.8% toward the trailing-twelve-month pace of +488.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 105.03M USD
- Year-over-year change
- +367.7%
- 4-year CAGR
- +12.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.03M | +367.7% |
| FY2024 | 2024-12-31 | (39.24M) | -18965.4% |
| FY2023 | 2023-12-31 | 208K | +100.9% |
| FY2022 | 2022-12-31 | (23.96M) | -136.3% |
| FY2021 | 2021-12-31 | 66.06M | — |
Investing Cash Flow vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 investing cash flow of $105.78M is the 2nd largest of the 10 companies compared; the peer median is $11.36M.
- Its year-over-year change of +488.7% is the highest of 10, against a peer median of +20.9%.
- Investing cash flow amounts to 727.5% of revenue for ABEO, versus a peer median of 176.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.44M | -525.4% | — | 176.4% | |
| LTM Mar 2026 | $105.78M | +488.7% | — | 727.5% | |
| LTM Mar 2026 | $92.35M | +117.8% | — | 253.0% | |
| LTM Mar 2026 | $64.92M | +335.2% | — | 230.0% | |
| LTM Mar 2026 | $35.25M | -20472.8% | — | 15.5% | |
| LTM Mar 2026 | $33.77M | +20.9% | -12.5% | 15008.9% | |
| LTM Mar 2026 | $12.86M | +116.9% | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $11.36M | +118.5% | — | — |
| LTM Mar 2026 | $831K | -41.0% | — | 41.2% | |
| LTM Mar 2026 | $59.66K | -89.1% | -69.0% | 0.1% | |
| Peer median (excluding ABEO) | $11.36M | +20.9% | -40.7% | 176.4% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Change in Working Capital | (18.26M) | (5.89M) | (1.79M) | (4.38M) | (5.39M) |
| Accounts Receivables | (3M) | 2.81M | (2.04M) | 792K | (5.06M) |
| Inventory | 0 | 0 | 0 | 0 | (5.49M) |
| Accounts Payables | (15.59M) | (9.11M) | 2.04M | (3.49M) | 6.54M |
| Other Working Capital | 324K | 404K | (3.83M) | (1.68M) | (1.37M) |
| Other Non-Cash Items | 24.15M | (5.52M) | 11M | 2.57M | (156.46M) |
| Operating Cash Flow | (65.67M) | (43.48M) | (37.01M) | (56.02M) | (76.33M) |
| Capital Expenditures | (4.15M) | (130K) | (331K) | (2.45M) | (7.98M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.16M) | (78.21M) | (51.64M) | (157.01M) | (206.63M) |
| Sales of Investments | 90.38M | 52.64M | 51.97M | 120.2M | 167.27M |
| Other Investing Activities | 0 | 1.73M | 204K | 18K | 152.37M |
| Investing Cash Flow | 66.06M | (23.96M) | 208K | (39.24M) | 105.03M |
| Debt Repayment | 0 | 0 | 0 | 20M | 0 |
| Common Stock Issued | 24.03M | 46.96M | 37.39M | 85.63M | 26.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 831K | (5K) | (332K) | (1.49M) | (37K) |
| Financing Cash Flow | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.26M | (24.27M) | 256K | 8.88M | 54.74M |
| Free Cash Flow | (69.82M) | (43.61M) | (37.34M) | (58.46M) | (84.3M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.